As per the research report, the size of the Europe Preimplantation Genetic Testing Market is valued at USD xx million in 2020 and estimated to be growing at a CAGR of xx%, to reach USD xx million by 2025 during the forecast period 2020-2025.
Preimplantation genetic detection is a method that examines the embryos that are creating using the process of in vitro fertilization. This facilitates the implantation of only selected fit embryos into the uterus thus making sure that a healthy baby is delivered. This prevents the carrying of genetic disorders into the family generations. The testing is done by a screening process wherein the healthy ones are frozen and stored.
The increasing occurrence of infertility around the world, growing support from public and private organizations in this field, rising medical facilities catering to patients with fertility issues, advancing technology in the field of genetics, awareness about chromosomal anomalies with the growing age of mother are all the factors that can be attributed to the growth of the preimplantation genetic testing market.
This research report segmented and sub-segmented into the following categories:
This region, because of increased focus on the R & D sector is expected to grow significantly in the future. The high financial status is also proposed to contribute to growth.
Key players operating in the Europe Preimplantation Genetic Testing Market profiled in this report are Illumina, Inc., Yikon Genomics, CooperSurgical, Oxford Gene Technology, Inc., Thermo Fisher Scientific, Inc., Rubicon Genomics, Inc., Agilent Technologies, Inc., Natera, Inc., Abbott Laboratories, PerkinElmer, Inc., and SciGene Corporation.
1. Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 Epidemology
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Procedure Type
5.1.1 Introduction
5.1.2 Preimplantation Genetic Screening
5.1.3 Preimplantation Genetic Screening
5.1.4 Y-o-Y Growth Analysis, By Procedure Type
5.1.5 Market Attractiveness Analysis, By Procedure Type
5.1.6 Market Share Analysis, By Procedure Type
5.2 Technology
5.2.1 Introduction
5.2.2 Next-Generation Sequencing
5.2.3 Polymerase Chain Reaction
5.2.4 Validation Biomarkers
5.2.5 Fluorescence in Situ Hybridization
5.2.6 Comparative Genomic Hybridization
5.2.7 Single-Nucleotide Polymorphism
5.2.8 Y-o-Y Growth Analysis, By Technology
5.2.9 Market Attractiveness Analysis, By Technology
5.2.10 Market Share Analysis, By Technology
5.3 Product and Service
5.3.1 Introduction
5.3.2 Reagents and Consumables
5.3.3 Instruments
5.3.4 Software and Services
5.3.5 Y-o-Y Growth Analysis, By Product and Service
5.3.6 Market Attractiveness Analysis, By Product and Service
5.3.7 Market Share Analysis, By Product and Service
5.4 Application
5.4.1 Introduction
5.4.2 Aneuploidy
5.4.3 Structural Chromosomal Abnormalities
5.4.3.1 Translocations
5.4.3.2 Deletions
5.4.3.3 Duplications
5.4.3.4 Inversions
5.4.4 Single Gene Disorders
5.4.5 X-Linked Disorders
5.4.6 HLA Typing
5.4.7 Gender Identification
5.4.8 Y-o-Y Growth Analysis, By Application
5.4.9 Market Attractiveness Analysis, By Application
5.4.10 Market Share Analysis, By Application
5.5 End users
5.5.1 Introduction
5.5.2 Maternity Centers & Fertility Clinics
5.5.3 Hospitals, Diagnostic Labs, and Service Providers
5.5.4 Research Laboratories & Academic Institutes
5.5.5 Y-o-Y Growth Analysis, By End users
5.5.6 Market Attractiveness Analysis, By End users
5.5.7 Market Share Analysis, By End users
6. Geographical Analysis
6.1 Introduction
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
6.1.3.1 By Geographical Area
6.1.3.2 By Procedure type
6.1.3.3 By Technology
6.1.3.4 By Product and Service
6.1.3.5 By Application
6.1.3.6 By End user
6.1.4 Market Attractiveness Analysis
6.1.4.1 By Geographical Area
6.1.4.2 By Procedure type
6.1.4.3 By Technology
6.1.4.4 By Product and Service
6.1.4.5 By Application
6.1.4.6 By End user
6.1.5 Market Share Analysis
6.1.5.1 By Geographical Area
6.1.5.2 By Procedure type
6.1.5.3 By Technology
6.1.5.4 By Product and Service
6.1.5.5 By Application
6.1.5.6 By End user
6.2 U.K
6.3 Spain
6.4 Germany
6.5 Italy
6.6 France
7. Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8. Market Leaders' Analysis
8.1 Illumina, Inc.
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 Thermo Fisher Scientific Inc.
8.3 Agilent Technologies, Inc.
8.4 Perkinelmer, Inc.
8.5 Coopersurgical, Inc.
8.6 ABBott Laboratories
8.7 Natera, Inc.
8.8 Rubicon Genomics, Inc.
9. Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10. Market Outlook and Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
